Revolution Medicines, Inc.
RVMDNASDAQHealthcare● Active
$147.67
$-1.56(-1.05%)
Market Cap$31.4B
P/E Ratio—
52W High$166.5
52W Low$34
Revolution Medicines, Inc. (RVMD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RVMD · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$2.29
Est. -$1.84 · -24.5%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS
RVMD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$1.96 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$1.84 | -$2.29 | -24.5% | — | $0.00B | — |
| ▼ Q1 FY2026 | Feb 25, 2026 | -$1.58 | -$1.86 | -17.7% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 5, 2025 | -$1.42 | -$1.61 | -13.4% | — | $0.00B | — |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.94 | -$1.31 | -39.4% | — | $0.03B | — |
| — Q2 FY2025 | May 7, 2025 | -$1.12 | -$1.13 | -0.9% | — | — | — |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$1.01 | -$1.12 | -10.9% | $0.26B | $0.00B | +75471.9% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.89 | -$0.94 | -5.2% | — | $0.00B | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$1.96
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$2.29
EPS Est.
-$1.84
EPS Surpr.
-24.5%
Revenue
—
Q1 FY2026
Feb 25, 2026Miss
EPS Actual
-$1.86
EPS Est.
-$1.58
EPS Surpr.
-17.7%
Revenue
—
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
-$1.61
EPS Est.
-$1.42
EPS Surpr.
-13.4%
Revenue
—
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$1.31
EPS Est.
-$0.94
EPS Surpr.
-39.4%
Revenue
—
Q2 FY2025
May 7, 2025
EPS Actual
-$1.13
EPS Est.
-$1.12
EPS Surpr.
-0.9%
Revenue
—
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$1.12
EPS Est.
-$1.01
EPS Surpr.
-10.9%
Revenue
$0.26B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.94
EPS Est.
-$0.89
EPS Surpr.
-5.2%
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-3.31 | $-1.68 | $-0.44 | 7 |
| Q3 FY2028 | $-3.19 | $-1.62 | $-0.43 | 12 |
| Q2 FY2028 | $-3.13 | $-1.59 | $-0.42 | 7 |
| Q1 FY2028 | $-3.21 | $-1.63 | $-0.43 | 7 |
| Q4 FY2027 | $-1.86 | $-0.94 | $-0.25 | 6 |
| Q3 FY2027 | $-2.27 | $-1.15 | $-0.30 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.2B | $0.3B | 4 |
| Q3 FY2028 | $0.1B | $0.2B | $0.3B | 9 |
| Q2 FY2028 | $0.1B | $0.2B | $0.3B | 6 |
| Q1 FY2028 | $0.1B | $0.1B | $0.3B | 4 |
| Q4 FY2027 | $0.1B | $0.3B | $0.6B | 5 |
| Q3 FY2027 | $0.1B | $0.3B | $0.4B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -24.5% | $147.21 | $151.07 | +2.62% |
| ▼ Q1 FY2026 | Feb 25, 2026 | -17.7% | $104.83 | $103.24 | -1.52% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -13.4% | $58.57 | $59.34 | +1.31% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -39.4% | $38.39 | $36.67 | -4.48% |
| ▲ Q2 FY2025 | May 7, 2025 | -0.9% | $37.44 | $37.66 | +0.59% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -10.9% | $41.34 | $40.50 | -2.03% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -5.2% | $56.75 | $59.42 | +4.70% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -5.2% | $43.29 | $42.27 | -2.36% |
Q2 FY2026+2.62%
Report Date
May 6, 2026
EPS Beat/Miss
-24.5%
Price Before
$147.21
Price After
$151.07
Q1 FY2026-1.52%
Report Date
Feb 25, 2026
EPS Beat/Miss
-17.7%
Price Before
$104.83
Price After
$103.24
Q4 FY2025+1.31%
Report Date
Nov 5, 2025
EPS Beat/Miss
-13.4%
Price Before
$58.57
Price After
$59.34
Q3 FY2025-4.48%
Report Date
Aug 6, 2025
EPS Beat/Miss
-39.4%
Price Before
$38.39
Price After
$36.67
Q2 FY2025+0.59%
Report Date
May 7, 2025
EPS Beat/Miss
-0.9%
Price Before
$37.44
Price After
$37.66
Q1 FY2025-2.03%
Report Date
Feb 26, 2025
EPS Beat/Miss
-10.9%
Price Before
$41.34
Price After
$40.50
Q4 FY2024+4.70%
Report Date
Nov 6, 2024
EPS Beat/Miss
-5.2%
Price Before
$56.75
Price After
$59.42
Q3 FY2024-2.36%
Report Date
Aug 7, 2024
EPS Beat/Miss
-5.2%
Price Before
$43.29
Price After
$42.27
Avg Beat Reaction+0.59%
Avg Miss Reaction-0.25%
Beat Rate1 / 8 quarters
Largest Move+4.70% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RVMD ends December
Revolution Medicines, Inc. (RVMD) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-2.29 — missing the analyst consensus of $-1.84 by -24.5%. The next RVMD earnings date is expected around September 1, 2026.
Each quarter, investors track RVMD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RVMD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RVMD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RVMD earnings · 5 questionsRevolution Medicines, Inc.'s next earnings report is expected around September 1, 2026. RVMD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RVMD historically reports after market close (AMC).
RVMD earnings datewhen is RVMD earningsRVMD next earnings datewhen does RVMD report earningsRVMD earnings calendar
▸ Source: FMP · Revolution Medicines, Inc. SEC filings · US GAAP · Revolution Medicines, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026